




IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Attorney Docket No.: **ABLE-0021**  
Inventors: **Secombes et al.**  
Serial No.: **10/088,780**  
Filing Date: **July 22, 2002**  
Examiner: **Kelly, Robert M.**  
Customer No.: **26259**  
Group Art Unit: **1632**  
Confirmation No.: **9521**  
Title: **Monoclonal Antibody 3F1H10  
Neutralising VHSV**

"Express Mail" Label No. EV540196193US  
Date of Deposit September 7, 2004

I hereby certify that this paper is being deposited with the United States Postal Service "Express Mail Post Office to Addressee" service under 37 CFR 1.10 on the date indicated above and is addressed to the Mail Stop Fee Amendment, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

By   
Typed Name: Kathleen A. Tyrrell, Reg. No. 38,350

Commissioner for Patents  
Washington, D.C. 20231

Dear Sir:

**SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT**

Pursuant to 37 C.F.R. §1.56 and in accordance with 37 C.F.R. §§1.97-1.98, information relating to the above-identified application is hereby disclosed. Inclusion of information in this statement is not to be construed as an admission that this information is material as that term is defined in 37 C.F.R. §1.56(b).

09/09/2004 CSHAU1 00000084 501619 10088780  
02 FC:1806 180.00 DA

( ) In accordance with §1.97(b), since this Information Disclosure Statement is being filed either within three months of the filing date of the above-identified application, within three months of the date of entry into the national stage of the above-identified application as set forth in §1.491, or before the mailing date of a first Office Action on the merits of the above-identified application, no additional fee is required.

**(XX)** In accordance with §1.97(c), this Information Disclosure Statement is being filed after the period set forth in §1.97(b) above but before the mailing date of either a Final Action under §1.113 or a Notice of Allowance under §1.311, therefore:

( ) Certification in Accordance with §1.97(e) is set forth below; or

**(XX)** The fee of \$180.00 as set forth in §1.17(p) is attached.

( ) In accordance with §1.97(d), this Information Disclosure Statement is being filed after the mailing date of either a Final Action under §1.113 or a Notice of Allowance under §1.311 but before the payment of the Issue Fee, therefore included are: Certification

in Accordance with §1.97(e); Petition Requesting  
Consideration of the Information Disclosure Statement;  
and the fee of \$130.00 as set forth in §1.17(i) (1).


- ( ) Copies of each of the references listed on the attached Form PTO-1449 (modified) are enclosed herewith.
- ( ) In accordance with §1.98(d), copies of some or all of the references listed on the attached Form PTO-1449 (modified) are not enclosed herewith because they were previously submitted to the U.S. Patent and Trademark Office in prior application Serial No. @@, filed @@ for which a claim for priority under 35 U.S.C. §120 has been made in the instant application.

Please charge any deficiency or credit any overpayment to Deposit Account No. 50-1619. This form is submitted in duplicate.

- ( ) The relevance of the listed references in a foreign language is as stated in the specification at pages @@.

(xx) All listed references are in the English language.


Respectfully submitted,

  
Kathleen A. Tyrrell  
Registration No. 38,350

Date: September 7, 2004

Licata & Tyrrell P.C.  
66 E. Main Street  
Marlton, New Jersey 08053

(856) 810-1515



Sheet 01 of 01

Form PTO-1449 Modified		Docket No. ABLE-0021	Serial No. 10/088,780
List of Patents and Publications Cited by Applicant (Use several sheets if necessary)		Applicant Urbaniak et al.	
U.S. Department of Commerce		Filing Date July 22, 2002	Group 1632

**OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)**

	AE	Prasad et al., "In vivo gene inoculation of a recombinant single-chain antitumor antibody induces anti-immunoglobulin response", <i>Cancer Gene Therapy</i> , Jul-Aug 1997 4:253-259

EXAMINER	DATE CONSIDERED
----------	-----------------